Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 37Neoplasms 30Colorectal Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Neoplasm Metastasis 5Rectal Neoplasms 3Multiple Myeloma 3Leukemia, Myeloid, Acute 3Glioma 3Colonic Neoplasms 3Breast Neoplasms 3Biliary Tract Neoplasms 3Thyroid Neoplasms 2Sarcoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Oligodendroglioma 2Lung Neoplasms 2Hematologic Neoplasms 2Glioblastoma 2Cholangiocarcinoma 2Brain Neoplasms 2Astrocytoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Solid Tumors 1Skin Neoplasms 1

Interventions

Paclitaxel 2trametinib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Letrozole 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cystadenocarcinoma, Serous × trametinib × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡